Literature DB >> 8282334

Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension.

E L Schiffrin1, L Y Deng, P Larochelle.   

Abstract

Seventeen male untreated mild essential hypertensive patients aged 41 +/- 2 years agreed to participate in a double-blind randomized trial to test the effects of antihypertensive treatment on the structure and function of subcutaneous resistance arteries. Patients were treated with either 50 to 100 mg/d atenolol or 2.5 to 5 mg/d cilazapril. Blood pressure before treatment was 148 +/- 6/99 +/- 1 and 147 +/- 2/99 +/- 1 mm Hg, respectively. At 1 year of treatment blood pressure was 131 +/- 4/85 +/- 2 and 132 +/- 2/87 +/- 1 mm Hg, respectively. Resistance arteries (200 to 400 microns lumen diameter) dissected from subcutaneous gluteal biopsies obtained before treatment and at 1 year showed that the media-lumen ratio of arteries from patients treated with cilazapril was reduced to 6.31 +/- 0.21% from 7.54 +/- 0.31% before treatment (P < .05), still slightly but significantly larger (P < .05) than the media-lumen ratio of resistance arteries of normotensive control subjects (5.15 +/- 0.30%). In contrast, in arteries from patients treated with atenolol there was no significant change with treatment (7.97 +/- 0.60% before and 8.07 +/- 0.45% after 1 year of treatment). Active wall tension responses to endothelin-1 were blunted in hypertensive patients and normalized in the cilazapril-treated patients. Depressed active media stress responses to norepinephrine, arginine vasopressin, and endothelin-1 were accordingly normalized in the patients receiving cilazapril as the media width became thinner but were unchanged in those taking atenolol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8282334     DOI: 10.1161/01.hyp.23.1.83

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  31 in total

Review 1.  Prehypertension: a possible target for antihypertensive medication.

Authors:  S D Nesbitt; S Julius
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

Review 2.  HOPE gives reason for hope. Heart Outcomes Prevention Evaluation.

Authors:  E L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

Review 3.  Why beta-blockers are not cardioprotective in elderly patients with hypertension.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

Review 4.  Inhibition of the renin angiotensin system: implications for the endothelium.

Authors:  Carmine Savoia; Ernesto L Schiffrin
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

Review 5.  Small artery remodelling in hypertension: causes, consequences and therapeutic implications.

Authors:  Michael J Mulvany
Journal:  Med Biol Eng Comput       Date:  2008-05       Impact factor: 2.602

Review 6.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 7.  Is there a link between the circulating renin-angiotensin system and coronary disease? A sceptical view.

Authors:  J D Swales
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 8.  Prehypertension: Underlying pathology and therapeutic options.

Authors:  Sulayma Albarwani; Sultan Al-Siyabi; Musbah O Tanira
Journal:  World J Cardiol       Date:  2014-08-26

Review 9.  Vascular Smooth Muscle Remodeling in Conductive and Resistance Arteries in Hypertension.

Authors:  Isola A M Brown; Lukas Diederich; Miranda E Good; Leon J DeLalio; Sara A Murphy; Miriam M Cortese-Krott; Jennifer L Hall; Thu H Le; Brant E Isakson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

10.  Role of CaMKII in Ang-II-dependent small artery remodeling.

Authors:  Anand M Prasad; Pimonrat Ketsawatsomkron; Daniel W Nuno; Olha M Koval; Megan E Dibbern; Ashlee N Venema; Curt D Sigmund; Kathryn G Lamping; Isabella M Grumbach
Journal:  Vascul Pharmacol       Date:  2016-09-20       Impact factor: 5.773

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.